New Triple-Threat therapy tested in battle against tough pancreatic cancer

NCT ID NCT04999969

Summary

This study is testing a new three-part treatment for people with advanced pancreatic cancer that has spread. It combines an experimental drug (AZD0171) with an existing immunotherapy (durvalumab) and standard chemotherapy. The main goals are to see if this combination is safe and if it helps patients live longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    La Jolla, California, 92037, United States

  • Research Site

    Los Angeles, California, 90025, United States

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    Ventura, California, 93003, United States

  • Research Site

    Atlanta, Georgia, 30318, United States

  • Research Site

    Coeur d'Alene, Idaho, 83814, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    Buffalo, New York, 14263, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Portland, Oregon, 97239, United States

  • Research Site

    San Antonio, Texas, 78229, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Seattle, Washington, 98195, United States

  • Research Site

    Madison, Wisconsin, 53792, United States

  • Research Site

    Barrie, Ontario, L4M 6M2, Canada

  • Research Site

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seongnam-si, 463-712, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Badalona, 08916, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Madrid, 28027, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Majadahonda, 28222, Spain

  • Research Site

    Pamplona, 31008, Spain

Conditions

Explore the condition pages connected to this study.